WebAug 12, 2024 · By BCRF August 12, 2024. Among the biggest headlines out of this year’s American Society of Clinical Oncology annual meeting were the results from the phase III … WebJul 15, 2024 · The PARP inhibitor Olaparib, has recently been evaluated in the Phase III OlympiAD trial, and demonstrated a significant progression-free survival advantage in patients with HER2-negative metastatic breast cancer and a germline BRCA-mutation. This article will review the findings and potential implications of the trial. Keywords: breast …
OlympiA Breast Cancer Trial Results 2024 BCRF
WebJun 20, 2024 · The OlympiAD-a phase III clinical trial that analyses the use of olaparib versus standard chemotherapy in HER2-negative metastatic BC with gBRCAm, found that progression-free survival was... WebJun 1, 2024 · 1052 Background: The OlympiAD study showed a significant progression-free survival (PFS) benefit for olaparib over chemotherapy treatment of physician’s choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm; HR 0.58, 95% CI 0.43–0.80). Objective response rate (ORR) was … iron bridge ontario news
Practice Olympiad Online
Web2 days ago · Reuters. The case against Fox News by Dominion Voting Systems is heating up just days before the trial is set to begin on Monday. Jury selection in the $1.6bn defamation lawsuit over the 2024 ... WebJun 4, 2024 · AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in … WebFeb 17, 2024 · Trial Results Lynparzas Olympia Win Could Broaden Breast Cancer Use February 17, 2024 Lynparza’s Olympia win could broaden breast cancer use Jacob Plieth The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed. port neches tx weather for next 10 days